Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting [Yahoo! Finance]
Vigil Neuroscience, Inc. (VIGL)
Company Research
Source: Yahoo! Finance
- Positive interim IGNITE Phase 2 data demonstrating iluzanebart (VGL101) as potential disease-modifying therapy for ALSP WATERTOWN, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the presentation of multiple oral and poster presentations on the Company's lead clinical candidate iluzanebart at the 2024 American Academy of Neurology (AAN) Annual Meeting. “We are excited to see our enthusiasm for iluzanebart matched by clinical leaders in the ALSP community. The interim findings from both the IGNITE Phase 2 and ILLUMINATE Natural History studies support the potential of iluzanebart to become the first, disease-modifying therapy for those living with ALSP,” said Petra Kaufmann, M.D., F.A.A.N, Chief Medical Officer of Vigil. “Both trials have led to an incredible step forward – not only in understand
Show less
Read more
Impact Snapshot
Event Time:
VIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIGL alerts
High impacting Vigil Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
VIGL
News
- Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological DiseasesBusiness Wire
- These 2 ‘Strong Buy' Penny Stocks Are Poised for a Massive Rally, Say Analysts [Yahoo! Finance]Yahoo! Finance
- Vigil Neuroscience to Present in Upcoming June Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Vigil Neuroscience to Present in Upcoming June Investor ConferencesGlobeNewswire
- All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
VIGL
Earnings
- 5/7/24 - Beat
VIGL
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- VIGL's page on the SEC website